An interventional study of MagPro X100 by MagVenture in Hoarding Disorder, Hoarding and Clutter, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
This study explores whether rapid non-invasive brain stimulation can help reduce hoarding disorder symptoms.
Hoarding disorder (HD) is characterized by difficulty letting go of possessions, leading to clutter that congests living spaces and impairs daily functioning. The majority of HD patients treated with cognitive behavioral therapy for HD usually experience considerable residual symptoms. New treatments are greatly needed. This study explores whether rapid non-invasive brain stimulation can help reduce hoarding disorder symptoms.
32 studies on the registry are indexed under Hoarding Disorder; 5 are open to participants now.
This study's planned enrollment of 10 is below the median of 37 across 28 interventional studies indexed under Hoarding Disorder.
Browse Hoarding Disorder studies →Stanford University is the lead sponsor of 2,168 studies on the registry; 431 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Theta-burst stimulation (a form of transcranial magnetic stimulation) targeting the right frontal pole.
Device: MagPro X100 by MagVenture
Participants will receive 5 session per day of TBS for 6 days (30 sessions total). Six treatment days have to occur within a 2 week period. Each session will be comprised of 1800 pulses, using a MagVenture MagPro X100.
Change in Compulsive Acquisition Scale (CAS)
The Compulsive Acquisition Scale (CAS) is an 18-item questionnaire that measures the extent to which individuals acquire and feel compelled to acquire possessions. The total score (sum of 18 items) ranges from 0 to 126. Total score higher than 48 shows significant difficulty with acquiring.
Time frame: Change from baseline to 3 weeks after treatment starts
Change in Hoarding Symptom Severity as Measured by Saving Inventory-Revised (SI-R)
The Saving Inventory-Revised scale (SI-R) is a 23-item questionnaire with 3 factor-analytically defined sub-scales for difficulty discarding, excessive clutter, and compulsive acquisition. The total score (sum of 23 items) ranges from 0 to 92. Total score higher than 41 shows significant difficulty with clutter. For the acquisition subscale, items 2 (reverse score), 9, 11, 14, 16, 18 and 21 are summed together. The subscale ranges from 0 to 28 and score greater than 13 indicates difficulty with excessive acquisition. For the difficulty discarding subscale, items 4(reverse score), 6, 7, 13, 17, 19, 23 are summed together. The subscale ranges from 0 to 28 and score greater than 13 indicates difficulty with discarding. For the clutter subscale, items 1, 3, 5, 8, 10, 12, 15, 20, 22 are summed together. The subscale ranges from 0 to 36 and score greater than 15 indicates difficulty with accumulated clutter.
Time frame: Change from baseline to 3 weeks after treatment starts
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.
Of 20 interventional studies with no phase under Hoarding Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 48. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.